| 0.6198 0.02 (3.28%) | 10-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.73  |
1-year : | 0.85 |
| Resists | First : | 0.62 |
Second : | 0.73 |
| Pivot price | 0.57 |
|||
| Supports | First : | 0.53 |
Second : | 0.47 |
| MAs | MA(5) : | 0.59 |
MA(20) : | 0.56 |
| MA(100) : | 0.55 |
MA(250) : | 0.72  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 79.4 |
D(3) : | 73.8 |
| RSI | RSI(14): 66.4 |
|||
| 52-week | High : | 1.83 | Low : | 0.34 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ IPSC ] has closed above the upper band by 6.8%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 22.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.63 - 0.63 | 0.63 - 0.63 |
| Low: | 0.59 - 0.59 | 0.59 - 0.59 |
| Close: | 0.62 - 0.62 | 0.62 - 0.62 |
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Mon, 27 Oct 2025
Century Therapeutics’ Long-Term Follow-Up Study: Key Insights for Investors - TipRanks
Mon, 20 Oct 2025
Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference - MyChesCo
Wed, 15 Oct 2025
Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference - The Manila Times
Sun, 12 Oct 2025
We Think Century Therapeutics (NASDAQ:IPSC) Needs To Drive Business Growth Carefully - Yahoo Finance
Wed, 08 Oct 2025
There Is A Reason Century Therapeutics, Inc.'s (NASDAQ:IPSC) Price Is Undemanding - simplywall.st
Wed, 10 Sep 2025
Century therapeutics (IPSC) CEO Pfeiffenberger sells $244 in stock - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 86 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 27.5 (%) |
| Held by Institutions | 41.8 (%) |
| Shares Short | 349 (K) |
| Shares Short P.Month | 1,460 (K) |
| EPS | -0.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.43 |
| Profit Margin | -20.4 % |
| Operating Margin | -25.2 % |
| Return on Assets (ttm) | -5.2 % |
| Return on Equity (ttm) | -10.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.04 |
| Sales Per Share | 1.32 |
| EBITDA (p.s.) | -0.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -115 (M) |
| Levered Free Cash Flow | 3 (M) |
| PE Ratio | -2.22 |
| PEG Ratio | 0 |
| Price to Book value | 0.25 |
| Price to Sales | 0.46 |
| Price to Cash Flow | -0.47 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|